VTI C3A CELLS
The semipermeable hollow fibers within the ELAD® cartridge allow two-way transfer between the VTL C3A cells and the patient’s plasma ultrafiltrate. Toxins, nutrients and dissolved oxygen pass from the patient’s plasma ultrafiltrate to the VTL C3A cells, while the potentially-beneficial macromolecules and other substances synthesized by the cells simultaneously pass into the patient’s ultrafiltrate, thus mimicking liver function.
The patient’s plasma ultrafiltrate is treated by our VTL C3A cells in a single session of continuous therapy lasting between three and ten days.
The ELAD® System has not been demonstrated to be safe or effective for any indication and is not available for sale in the United States or any other country.
CAUTION - Investigational New Drug. Limited by Federal (or United States) law to investigational use.
Address: floor 1, block B (21b), neijuxuan workshop, comprehensive bonded zone, No. 33688, jingshidong Road, Jinan area, China (Shandong) pilot Free Trade Zone Telephone:
Copyright: Shandong yiruite Biotechnology Co., Ltd Record No:鲁ICP备20021086 Sign in